
    
      This clinical trial was designed as a multicenter, single-arm, and open-label clinical trial.

      Evaluate the incidence of coronary artery lesions in the 7th week of IVIG-SN administration,
      compared to the incidence of coronary artery lesions among untreated Kawasaki patients, to
      prove the superior efficacy of IVIG-SN.
    
  